Helsinn signs distribution agreement with Immedica Pharma
Helsinn brings cancer pain management option to China
Helsinn invests €1 million in Gain Therapeutics
Approval of AKYNZEO oral formulation in Korea
Helsinn and the Scientific Centre of Monaco collaborate
Orphan drug designation for AML treatment
Helsinn Pharmaceuticals opens office in Shanghai, China
Helsinn Investment Fund leads financial round in GreenBone
Helsinn appoints Eric Cornut to Board of Directors
Patient-driven innovations for cancer sufferers
Helsinn Group and MEI Pharma to develop acute myeloid leukaemia treatment
Latest EU drug approvals span range of health issues
Cancer anorexia–cachexia – anamorelin